Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $33.19M | $18.82M | $15.40M | $20.49M | N/A | N/A |
| Cost of Revenue | $1.94M | $2.84M | $123.04M | $108.47M | $74.06M | $54.22M | $807.00K | $669.00K |
| Gross Profit | $-1.94M | $-2.84M | $-89.85M | $-89.65M | $-58.66M | $-33.73M | $-807.00K | $-669.00K |
| Gross Margin | 0.00% | 0.00% | -270.69% | -476.47% | -380.83% | -164.58% | 0.00% | 0.00% |
| Operating Expenses | $250.12M | $168.45M | $44.52M | $40.27M | $28.22M | $20.82M | $49.88M | $24.36M |
| Operating Income | $-252.05M | $-171.29M | $-134.37M | $-129.92M | $-86.88M | $-54.54M | $-50.69M | $-25.03M |
| Operating Margin | 0.00% | 0.00% | -404.81% | -690.48% | -564.03% | -266.16% | 0.00% | 0.00% |
| Net Income | $-246.29M | $-165.79M | $-134.50M | $-131.80M | $-86.48M | $-51.00M | $-49.33M | $-25.00M |
| Net Margin | 0.00% | 0.00% | -405.21% | -700.46% | -561.47% | -248.88% | 0.00% | 0.00% |
| EPS (Basic) | $-2.47 | $-1.99 | $-2.21 | $-3.59 | $-2.77 | $-1.80 | $-3.15 | $-1.40 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |